Innoviva appoints Pavel Raifeld as CEO

– USA, CA –  Innoviva, Inc. (NASDAQ: INVA), today announced the appointment of Pavel Raifeld as CEO effective May 20, 2020. Mr. Raifeld replaces Geoff Hulme, who served as the principal executive officer since May 2018.

Mr. Raifeld is a seasoned healthcare executive with a strong background in strategy, business development and corporate finance and has focused much of his career on the creation of significant shareholder value.

 “We are excited to have Pavel join us. We believe the Company will benefit from his background and experience as the Company continues to move forward on the Board’s strategy to maximize shareholder value and its focus on capital allocation. On behalf of the Board and all Innoviva employees, I would also like to thank Geoff for his commitment and many contributions to the Company.” said Dr. Odysseas Kostas, Board Chairman.

About Pavel Raifeld

Prior to joining Innoviva, Pavel Raifeld, CFA, served on the investment team at Sarissa Capital Management LP, an investment management firm focused on improving strategies of companies to enhance shareholder value. Earlier, he was a senior member of the healthcare investment banking team at Credit Suisse (USA) LLC. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey & Company, Inc. and The Boston Consulting Group Ltd.

Mr. Raifeld said, “I am honored by and excited about the opportunity to lead Innoviva. I look forward to working alongside the experienced Board and talented team to build an even brighter future for this great company.”

Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.

About Innoviva

Innoviva, Inc. is a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, including RELVAR/BREO ELLIPTA, ANORO ELLIPTA and TRELEGY ELLIPTA. Under the Long-Acting Beta2 Agonist Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva is also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC, relating to TRELEGY ELLIPTA and any other product or combination of products that may be discovered and developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR/BREO ELLIPTA and ANORO ELLIPTA.

ANORO, RELVAR, BREO, TRELEGY and ELLIPTA are trademarks of the GlaxoSmithKline group of companies.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.